Brief: Gossamer Bio Announces First Quarter 2023 Financial Results

Gossamer Bio

09/05/2023 21:22

May 9 (Reuters) - Gossamer Bio Inc  GOSS.O :
    * GOSSAMER BIO ANNOUNCES FIRST QUARTER 2023 FINANCIAL
RESULTS AND
PROVIDES BUSINESS UPDATE
    * REGISTRATIONAL PHASE 3 CLINICAL TRIAL IN PAH PATIENTS
EXPECTED
TO INITIATE IN 3Q23 -
    * INITIAL TORREY STUDY OPEN-LABEL EXTENSION DATA EXPECTED
MID 2023
    * $202 MILLION IN CASH, CASH EQUIVALENTS & MARKETABLE
SECURITIES,
AS OF MARCH 31, 2023
    * OPERATIONAL RESTRUCTURING IMPLEMENTED TO PRIORITIZE
SERALUTINIB
    * GOSSAMER - SEES CURRENT CASH,CASH EQUIVALENTS,MARKETABLE
SECURITIES SUFFICIENT TO FUND OPERATIONS THROUGH NEXT 12 MONTHS
FROM DATE OF Q1 FINANCIAL STATEMENTS
    * GOSSAMER BIO - AS PART OF STRUCTURAL REORGANIZATION TO
CENTER CO
AROUND SERALUTINIB AND CONTINUED DEVELOPMENT IN PAH, CO REDUCED
HEADCOUNT BY OVER 25%
    * NET LOSS FOR THE QUARTER ENDED MARCH 31, 2023, WAS $49.2
MILLION, OR $0.52 PER SHARE
    * Q1 EARNINGS PER SHARE VIEW $-0.53 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw5rg61ca 
Further company coverage:  GOSS.O 

 ((Reuters.Briefs@thomsonreuters.com;))